NFL Notebook: Bucs CB Talib suspended 4 games
By Wire Reports
Published: Saturday, October 13, 2012, 8:46 p.m.
Updated: Saturday, October 13, 2012
TAMPA, Fla. — Tampa Bay's defense was jolted Saturday when the NFL suspended cornerback Aqib Talib four games without pay for violating the league's policy on performance-enhancing substances.
The fifth-year pro said in a statement released by the team that he took an Adderall pill without a prescription “around the beginning of training camp.” He will not appeal the ban, which begins Sunday against the Kansas City Chiefs.
Talib, 26, was the 20th overall pick in the 2008 draft and is one of the team's top defenders with 18 career interceptions. He also will be eligible to return to the active roster on Nov. 5.
“I made a mistake by taking an Adderall pill without a prescription. This is especially regrettable because, for the past several months, with Coach (Greg) Schiano's help, I've worked very hard to improve myself — professionally and personally — as a player and a man,” Talib said.
Buffalo signs two players
The Buffalo Bills signed defensive tackle Jay Ross and offensive lineman David Snow from their practice squad.
Odds and ends
The NFL fined Cardinals receiver Larry Fitzgerald $7,875 for facemasking St. Louis Rams cornerback Janoris Jenkins last week. ... Fourteen players are listed as questionable for Sunday's game at Seattle, including WR Wes Welker (ankle) and tight ends Rob Gronkowski (hip) and Aaron Hernandez (ankle). Hernandez did not practice Friday. ...RB Donald Brown didn't travel with the Colts to play the Jets.
- On eve of first offseason practices, Steelers might be forced to rely on rookies in 2013
- Ex-Steelers QB Batch learns new form of 2-minute drill
- Steelers ink fourth-round pick Thomas to 4-year deal
- Steelers’ Clark: Polamalu third-best safety in NFL
- Undrafted lineman Embernate hopes he can stick with Steelers
- Steelers Hall of Famer Jack Butler dies at 85
You must be signed in to add comments
To comment, click the Sign in or sign up at the very top of this page.
Subscribe today! Click here for our subscription offers.